HealthQuill Novartis
Novartis AG is set to buy a German-based biotechnology company, MorphoSys AG, for $2.9 billion, giving the Swiss firm access to a key drug for treating blood cancer.
Drugs Health Pharma

Novartis to buy MorphoSys for $2.9 billion to expand cancer portfolio

HQ Team February 6, 2024: Novartis AG is set to buy a German-based biotechnology company, MorphoSys AG, for $2.9 billion, giving the Swiss.

Read More
The USFDA is probing cancer therapies of Gilead Sciences, Johnson & Johnson and Novartis following reports of malignancies in patients who received treatment.
Drugs Health Pharma

FDA probing T cell cancer therapies of Gilead Sciences, Novartis, J & J

HQ Team November 29, 2023: The USFDA is probing cancer therapies of Gilead Sciences, Johnson & Johnson and Novartis following reports of malignancies.

Read More
Novartis, one of the world’s top five pharmaceutical companies by revenue, has filed a lawsuit against two US government health agencies, terming drug price negotiations initiated by them as “unconstitutional.”
Drugs Health Pharma

Novartis takes US government to court on drug price negotiations

HQ Team September 2, 2023: Novartis, one of the world’s top five pharmaceutical companies by revenue, has filed a lawsuit against two US.

Read More
Drugs Health Medical Pharma

Novartis’ Kisqali shows 25% reduction in breast cancer recurrence

HQ Team June 3, 2023: Novartis breast cancer drug Kisqali cut the risk of recurrence of the disease by more than 25% in.

Read More
Cipla Ltd has agreed with Novartis Pharma AG to market and manufacture the Swiss-based company’s Galvus brand for treating type 2 diabetes.
Drugs Health Medical Pharma

Cipla, Novartis team up to make, market anti-diabetic drug

HQ Team April 10, 2023: Cipla Ltd has agreed with Novartis Pharma AG to market and manufacture the Swiss-based company’s Galvus brand for.

Read More
X